Rezzayo is indicated to be given as a weekly intravenous drip for a minimum of 14 days until Candida is no longer present in the bloodstream. Credit: TommyStockProject / Shutterstock.com.
The fungal infection is caused by the yeast candida, which can affect areas of the body such as the blood and vital organs.
Rezzayo is given as a weekly intravenous drip for at least 14 days until candida is no longer present in the bloodstream.
Rezafungin is the active ingredient of the treatment and works by inhibiting an enzyme essential for fungal cell wall synthesis, rendering the fungal cells fragile and halting their growth.
The approval of Rezzayo is based on the results of a Phase III randomised, double-blind and controlled clinical trial.
MHRA healthcare quality and access interim executive director Julian Beach said: “Keeping patients safe and enabling their access to high quality, safe and effective medical products are key priorities for us.
“We’re assured that the appropriate regulatory standards for the approval of this medicine have been met. As with all products, we will keep its safety under close review.”
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.